APB-R3
Stage unconfirmedA candidate for atopic dermatitis and other inflammatory diseases, licensed to Evommune in the US in 2024.
FROM PUBLIC EVENTS · 2026-11-18
Pipeline reshaping After a large investment, it switched from sequential to parallel development of candidates and grew its team. Also seen: Discovery · preclinical
Roles often seen at this stageResearch & development · BD & licensing
Founded in 2013, it develops antibody drugs for autoimmune and inflammatory diseases using its HuDVFab human antibody library and its half-life-extending SAFA platform.
A candidate for atopic dermatitis and other inflammatory diseases, licensed to Evommune in the US in 2024.
A candidate for thyroid eye disease and other autoimmune diseases, licensed to Lundbeck in 2021.
An inflammatory bowel disease candidate unveiled at its R&D Day in November 2026.
Its in-house platform for extending the half-life of antibody fragments in the body.
Completed a 346.8 billion won third-party share placement with TKG Huchems and IMM.
Unveiled candidates for inflammatory bowel disease (APB-I-005), dyslipidemia (APB-O-001) and a cancer ADC (APB-A-001) at its R&D Day.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.